888-969-2592
Kalkine 0
countryflagCA

Cardiol Therapeutics Inc Class A

Healthcare CA CRDL

1.8CAD
-(-%)

Last update at 2025-07-14T16:24:00Z

Day Range

1.771.87
LowHigh

52 Week Range

1.093.57
LowHigh

Fundamentals

  • Previous Close 1.80
  • Market Cap152.08M
  • Volume92532
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-40.19076M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.08M
  • Diluted EPS TTM-0.47

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -30.93065M -31.63824M -20.64093M -13.68402M -15.89373M
Minority interest - - - - -
Net income -11.52226M -31.74424M -20.67539M -13.78387M -15.89373M
Selling general administrative 22.37M 27.87M 9.95M 10.45M 5.87M
Selling and marketing expenses - - - - -
Gross profit - 0.08M - - -
Reconciled depreciation 0.22M 0.22M 0.23M 0.15M 0.09M
Ebit -50.33903M -45.47313M -20.60648M -13.58355M -15.23036M
Ebitda -50.11913M -45.25271M -20.37694M -13.43298M -15.13887M
Depreciation and amortization 0.22M 0.22M 0.23M 0.15M 0.09M
Non operating income net other - - - - -
Operating income -50.33903M -45.47313M -20.60648M -13.58355M -7.49374M
Other operating expenses 41.34M 38.74M 20.69M 14.13M 7.49M
Interest expense 19.41M 0.11M 0.00000M 0.00062M 0.66M
Tax provision - - 0.00000M - -
Interest income 1.24M 6.91M 0.04M 0.15M 7.74M
Net interest income 1.24M 0.11M 0.08M 0.24M -0.56007M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -19.40839M 0.11M 0.03M 0.10M -
Total revenue 0.00000M 0.08M 0.00000M 0.00000M 0.00000M
Total operating expenses 41.34M 38.74M 20.69M 14.13M 7.49M
Cost of revenue - - - - -
Total other income expense net 19.41M 13.83M -0.03445M -0.10047M -8.40000M
Discontinued operations - - - - -
Net income from continuing ops -30.93065M -31.63824M -20.64093M -13.68402M -15.89373M
Net income applicable to common shares -30.93065M -31.63824M -20.64093M -13.68402M -15.89373M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 31.86M 36.70M 62.03M 87.88M 15.89M
Intangible assets - 0.21M 0.29M 0.38M 0.46M
Earning assets - - - - -
Other current assets - 0.94M - 2.83M 0.69M
Total liab 7.14M 8.45M 9.83M 11.64M 2.62M
Total stockholder equity 24.73M 28.25M 52.20M 76.24M 13.27M
Deferred long term liab - - - - -
Other current liab - 8.28M 9.75M 11.52M 2.47M
Common stock - 148.52M 147.55M 142.92M 51.92M
Capital stock 179.34M - 147.55M 142.92M 51.92M
Retained earnings -179.25410M -142.57680M -114.44851M -83.51786M -51.87962M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M - - -
Cash 30.58M 34.87M 59.47M 83.90M 14.03M
Cash and equivalents - - 59.47M 83.90M 14.03M
Total current liabilities 7.01M 8.30M 9.80M 11.57M 2.52M
Current deferred revenue - -7.62469M - - -
Net debt - -34.69556M -59.39700M -83.78149M -13.86862M
Short term debt - 0.02M 0.05M 0.04M 0.05M
Short long term debt - - - - -
Short long term debt total - 0.17M 0.07M 0.12M 0.16M
Other stockholder equity - 18.79M 19.10M 16.84M 13.23M
Property plant equipment - - 0.30M 0.36M 0.48M
Total current assets 31.67M 36.15M 61.44M 87.14M 14.95M
Long term investments - - - - -
Net tangible assets - - 51.91M 75.86M 12.81M
Short term investments - 0.06M - - -
Net receivables 0.10M 0.28M 0.48M 0.41M 0.22M
Long term debt - - - - -
Inventory - - - 0.34M 0.02M
Accounts payable - 7.62M 9.33M 4.14M 1.77M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 3.52M - - -0.22141M
Additional paid in capital - - - - -
Common stock total equity - - - - 51.92M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00000M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.20M 0.55M 0.59M 0.74M 0.94M
Capital lease obligations 0.16M - 0.07M 0.12M 0.16M
Long term debt total - - 0.02M 0.07M 0.10M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.07471M -0.01292M -0.04060M -0.42430M -0.01379M
Change to liabilities 4.47M 2.39M 1.83M -1.50132M 1.96M
Total cashflows from investing activities -0.07471M -0.01292M -0.04060M -0.42430M -0.01379M
Net borrowings -0.05393M -0.05192M -0.05047M -0.02019M 12.07M
Total cash from financing activities -0.05393M 93.44M 16.30M 2.03M 25.28M
Change to operating activities 1.42M -2.27459M -0.06414M 0.23M -0.49023M
Net income -30.93065M -31.63824M -20.64093M -13.68402M -15.89373M
Change in cash -24.42920M 69.87M 7.07M -9.77530M 14.37M
Begin period cash flow 83.90M 14.03M 6.96M 16.73M 2.36M
End period cash flow 59.47M 83.90M 14.03M 6.96M 16.73M
Total cash from operating activities -27.22034M -23.55078M -9.18543M -11.38008M -10.89400M
Issuance of capital stock 0.00000M 84.08M 17.25M 1.67M 14.23M
Depreciation 0.22M 0.22M 0.23M 0.15M 0.09M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.00000M 0.02M 1.10M 0.14M -6.34553M
Change to account receivables -0.14418M -0.05995M 0.71M -0.46709M -0.33106M
Sale purchase of stock 0.00000M 98.73M 17.43M 2.05M 14.23M
Other cashflows from financing activities -0.07471M 9.41M -0.90451M 0.38M 11.05M
Change to netincome -2.25762M 7.79M 2.91M 3.77M 9.66M
Capital expenditures 0.07M 0.01M 0.04M 0.42M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 5.75M 0.08M 8.32M -1.62066M -5.20213M
Stock based compensation 5.01M 8.50M 2.77M 3.27M 1.65M
Other non cash items -7.27081M -0.70731M 0.14M 0.51M 8.46M
Free cash flow -27.29505M -23.56369M -9.22603M -11.80438M -10.90780M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRDL
Cardiol Therapeutics Inc Class A		 - -% 1.80 - - 1273.79 8.22 230.52 0.41
BHC
Bausch Health Companies Inc		 -0.19 2.16% 8.59 - 1.69 0.32 18.74 2.33 8.07
CRON
Cronos Group Inc		 0.01 0.35% 2.88 13.68 - 8.04 0.67 0.02 -1.9458
CURA
Curaleaf Holdings Inc.		 -0.01 0.63% 1.58 - 138.89 0.62 0.72 1.00 5.90
GUD
Knight Therapeutics Inc.		 - -% 6.13 60.30 80.65 1.61 0.76 1.27 6.84

Reports Covered

Stock Research & News

View All

Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc Class A

2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5

Key Executives

Name Title Year Born
Mr. David G. Elsley M.B.A., MBA Pres, CEO & Director NA
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, M.B.A., MBA CFO, Corp. Sec. & Director NA
Mr. Bernard Lim B.Sc. Chief Operating Officer NA
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer & Head of R&D 1962
Trevor Burns Investor Relations NA
Mr. David G. Elsley MBA President, CEO & Director NA
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA CFO, Corporate Secretary & Director NA
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer & Head of Research & Development 1962
Mr. John A. Geddes BSCPT, MBA Vice President of Corporate Development NA
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer and Head of Research & Development 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.